公司資料
Incyte 股價、新聞與催化劑
- 股票代碼:
- INCY
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Wilmington, Delaware
股票表現
123.50 USD (+2.78%)
收盤價
最後更新: 2026年8月17日
18.4B USD
市值
股價為何變動
As of Aug 17, 2026, INCY closed up 2.78% at $123.50. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Incyte is a biopharmaceutical company focused on hematology, oncology, and inflammation. Its business combines a commercial base with a pipeline that continues to produce new opportunities in immunology and cancer.
所在地與產業分類
Headquartered in Wilmington, Delaware and listed on NASDAQ, Incyte is a U.S.-based biotech with meaningful global commercial and development exposure. It sits in specialty biopharma rather than general healthcare.
商業模式特徵
The company generates value through marketed products, R&D, and pipeline expansion across oncology and inflammatory disease. Investors track revenue durability, new data, and whether the next wave of programs can keep replacing mature growth.
生技產業定位
Incyte is a well-established biotech name with enough commercial scale to soften pure binary risk, but it still reacts to clinical data and label expansion. It sits in a strong middle ground between mature pharma and high-volatility development biotech.
未來催化劑
- Incyte’s near-term catalysts are Opzelura growth, povorcitinib readouts, and any label-expansion or pipeline update in dermatology and oncology. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。